Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
LanZhou Foci Pharmaceutical Co., Ltd. specializes in the production of generic and specialty pharmaceuticals, primarily focusing on the Chinese market. The company differentiates itself through a robust pipeline of over 100 products, including antibiotics and cardiovascular drugs, which are critical in addressing local healthcare needs.
LanZhou Foci generates revenue primarily through the sale of generic drugs, leveraging its cost-efficient production processes and established distribution networks. The company benefits from pricing power in the domestic market due to its extensive product portfolio and strong relationships with healthcare providers.
Regulatory approvals for new drug applications
Changes in healthcare policies affecting drug pricing
Market share shifts in the generic drug segment
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes in drug approval processes
Increased competition from both domestic and international generic manufacturers
Emergence of biosimilars that could cannibalize market share
Price erosion in the generic drug market due to increased competition
Low return on equity (2.9%) indicating potential inefficiencies in capital utilization
Limited financial flexibility due to low operating margins (7.2%)
moderate - As a pharmaceutical manufacturer, LanZhou Foci's performance is somewhat insulated from economic cycles, but healthcare spending can be influenced by GDP growth and consumer confidence.
Interest rates impact the company's cost of capital and can affect consumer spending on healthcare. Higher rates may compress valuations as future cash flows are discounted at a higher rate.
minimal - The company has low debt levels (Debt/Equity of 0.04), reducing its sensitivity to credit market fluctuations.
value - Investors may be attracted to the stock due to its low valuation metrics despite recent performance challenges.
moderate - The stock has shown significant price fluctuations, with a 1-year return of -16.5%, indicating potential volatility.
